Zura Bio's (ZURA) "Buy" Rating Reaffirmed at Chardan Capital

Key Points

• The stock of Zura Bio (NASDAQ:ZURA) has been given a "buy" rating by Chardan Capital, with a target price of $10.00, indicating a potential upside of 481.40% from its current price.
• Despite a positive outlook from Chardan Capital, Oppenheimer has lowered its price target for Zura Bio from $19.00 to $17.00, maintaining an "outperform" rating.
• Zura Bio's stock recently increased by 8.2%, and the company reported earnings of ($0.17) per share, exceeding analysts' expectations.

Zura Bio (NASDAQ:ZURA - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at Chardan Capital in a research note issued to investors on Friday,Benzinga reports. They currently have a $10.00 price objective on the stock. Chardan Capital's price target indicates a potential upside of 471.43% from the stock's previous close.

Separately, Oppenheimer dropped their target price on Zura Bio from $19.00 to $17.00 and set an "outperform" rating for the company in a research note on Friday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $14.00.

Zura Bio Stock Up 1.2%

Shares of ZURA traded up $0.02 on Friday, hitting $1.75. 59,417 shares of the stock traded hands, compared to its average volume of 514,256. Zura Bio has a 1 year low of $0.97 and a 1 year high of $5.07. The stock's 50 day moving average is $1.39 and its two-hundred day moving average is $1.32. The firm has a market capitalization of $119.67 million, a P/E ratio of -2.50 and a beta of -0.06.

Zura Bio (NASDAQ:ZURA - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.02. Research analysts forecast that Zura Bio will post -0.65 EPS for the current year.

Institutional Investors Weigh In On Zura Bio

Several institutional investors have recently bought and sold shares of the business. Two Sigma Advisers LP acquired a new stake in shares of Zura Bio in the fourth quarter worth $32,000. Savant Capital LLC raised its position in Zura Bio by 190.4% in the second quarter. Savant Capital LLC now owns 32,409 shares of the company's stock valued at $34,000 after purchasing an additional 21,249 shares during the period. ProShare Advisors LLC purchased a new position in Zura Bio in the fourth quarter valued at about $35,000. XTX Topco Ltd acquired a new position in shares of Zura Bio during the fourth quarter worth about $44,000. Finally, Wells Fargo & Company MN boosted its position in shares of Zura Bio by 68.6% in the fourth quarter. Wells Fargo & Company MN now owns 23,053 shares of the company's stock worth $58,000 after buying an additional 9,379 shares during the period. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.